United States · FDA National Drug Code directory
ENGERIX-B
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 58160-821_b3c5a55f-bf21-4cea-9fce-715face6eeb0
- Product NDC
- 58160-821
- Form
- INJECTION, SUSPENSION
- Composition / generic term
- Hepatitis B Vaccine (Recombinant)
- Labeler
- GlaxoSmithKline Biologicals SA
- Marketing category
- BLA
- Marketing start / end (source format)
- 20070328
- Source listing expiry
- 20271231
Source-listed ingredients
- HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN — 20 ug/mL
These values do not establish equivalence or a dose recommendation.
Packages
- 10 VIAL in 1 CARTON (58160-821-11) / 1 mL in 1 VIAL (58160-821-01) · 58160-821-11
- 10 SYRINGE in 1 CARTON (58160-821-52) / 1 mL in 1 SYRINGE (58160-821-43) · 58160-821-52
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →